IMPL.Q Stock Overview
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IPI Legacy Liquidation Co Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.015 |
| 52 Week High | US$2.87 |
| 52 Week Low | US$0.007 |
| Beta | 0.38 |
| 1 Month Change | 97.37% |
| 3 Month Change | -86.49% |
| 1 Year Change | -98.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump
Apr 17
The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 30Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%
Mar 26Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M
Aug 15Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people
Jul 19Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Jun 28Impel NeuroPharma reports Q1 results
Jun 07Shareholder Returns
| IMPL.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.9% | -3.3% | -2.2% |
| 1Y | -98.9% | -1.9% | 23.9% |
Return vs Industry: IMPL.Q underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: IMPL.Q underperformed the US Market which returned 25.9% over the past year.
Price Volatility
| IMPL.Q volatility | |
|---|---|
| IMPL.Q Average Weekly Movement | 97.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMPL.Q's share price has been volatile over the past 3 months.
Volatility Over Time: IMPL.Q's weekly volatility has increased from 78% to 98% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 160 | n/a | impelpharma.com |
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022.
IPI Legacy Liquidation Co Fundamentals Summary
| IMPL.Q fundamental statistics | |
|---|---|
| Market cap | US$358.50k |
| Earnings (TTM) | -US$74.28m |
| Revenue (TTM) | US$20.99m |
0.0x
P/S Ratio0.0x
P/E RatioIs IMPL.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMPL.Q income statement (TTM) | |
|---|---|
| Revenue | US$20.99m |
| Cost of Revenue | US$9.95m |
| Gross Profit | US$11.04m |
| Other Expenses | US$85.31m |
| Earnings | -US$74.28m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.11 |
| Gross Margin | 52.58% |
| Net Profit Margin | -353.93% |
| Debt/Equity Ratio | -120.8% |
How did IMPL.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/08 17:11 |
| End of Day Share Price | 2024/04/05 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IPI Legacy Liquidation Co is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yatin Suneja | Guggenheim Securities, LLC |
| Dana Flanders | Guggenheim Securities, LLC |
| Kenneth Cacciatore | TD Cowen |